CMB 305

Drug Profile

CMB 305

Alternative Names: CMB-305; G-305/LV-305; ID-CMB305; ID-G305/ID-LV305; ID-LV305/ID-G305; LV 305 + G 305

Latest Information Update: 08 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immune Design
  • Developer Genentech; Immune Design
  • Class Cancer vaccines; Peptide vaccines; Peptides; RNA; RNA vaccines
  • Mechanism of Action Dendritic cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Synovial sarcoma
  • Phase II Soft tissue sarcoma
  • Phase I Solid tumours

Most Recent Events

  • 08 Aug 2018 Phase-I development in Solid-tumours (In the elderly, Locally recurrent, Metastatic disease, Monotherapy, In adults) is underway in USA (Parenteral, Injection) (NCT02387125)
  • 01 Jun 2018 Phase-III clinical trials in Synovial sarcoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Monotherapy, Second-line therapy or greater, In children, In adolescents, In adults, In the elderly) in USA (Parenteral) (NCT03520959)
  • 14 Mar 2018 Updated efficacy data from a from a phase Ib trial in Soft tissue sarcoma released by Immune Design
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top